miRNA143 Induces K562 Cell Apoptosis Through Downregulating BCR-ABL

Liang, Bing; Song, Yong; Wen-ling, Zheng; Ma, Wenxue

doi:10.12659/msm.895833

Cited by 8 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4a-c), suggesting that S.c-EVs are effective delivery vectors for the tested agents. In a previous study, it's demonstrated that mice receiving an intranasal dose of EV-miR-143 (an apoptosisinducing miRNA as reported previously 5 ) exhibited signi cant inhibition of HeLa tumor growth 25 . We investigated if S.c-EVs could deliver miRNA to tumor tissue and inhibit implanted Hela tumor growth.…”

Section: In Vitro and In Vivo Targeted Delivery Of Therapeutic Agents...mentioning

confidence: 63%

Delivery of therapeutic RNA by extracellular vesicles derived from Saccharomyces cerevisiae for Medicine Applications

Yuan,

Ma,

Liu

et al. 2024

Preprint

View full text Add to dashboard Cite

Employing small extracellular vesicles (EVs) as drug delivery vehicles presents a plethora of advantages over conventional drug delivery methods, including biological compatibility, engineering versatility for targeted delivery, and biodegradability. Therefore, strategies aimed at amplifying their therapeutic potential involve developing efficient, tissue-specific, and non-immunogenic delivery approaches. Despite rapid advancements in the realm of EVs as drug delivery systems in recent years, the availability of a high-yield, reproducible, and cost-effective source for EVs production and isolation remains a limiting factor for practical application. In this study, we isolated EVs from Saccharomyces cerevisiae (S.c) and loaded them with cargoes such as hsa-miR-143 (an apoptosis-inducing miRNA) or miR-H6 (a miRNA targeting HSV-1). We demonstrated the capability of these EVs to deliver microRNAs or even large mRNA to a variety of cell types. The therapeutic potential of S.c-derived EVs (S.c-EVs) was further evidenced by their ability to inhibit tumor growth in animal models. The S.c-EVs proved to be safe and non-immunogenic in vivo. Our results suggest that Saccharomyces cerevisiae represents a cost-effective source of extracellular vesicles, serving as nanocarriers for functional drug delivery in therapeutic applications.

show abstract

Section: In Vitro and In Vivo Targeted Delivery Of Therapeutic Agents...mentioning

confidence: 63%

Delivery of therapeutic RNA by extracellular vesicles derived from Saccharomyces cerevisiae for Medicine Applications

Yuan,

Ma,

Liu

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Repression of miR-143 via methylation seems to enhance KMT2A - AFF1 oncogene expression, whereas upregulation of this miRNA could be a therapeutic target for this ALL subgroup [ 141 ]. In the same context, miR-143 overexpression in ALL cells in vitro resulted in growth inhibition and induction of apoptosis by either silencing DNMT3A (DNA methyltransferase 3 alpha) or by downregulating BCR - ABL1 expression in the respective cases [ 142 , 143 ]. A recent study reported significant upregulation of miR-145, which is clustered with miR-143, although this qRT-PCR study included only 13 pediatric ALL cases and 5 controls [ 36 ].…”

Section: Resultsmentioning

confidence: 99%

MicroRNAs and the Diagnosis of Childhood Acute Lymphoblastic Leukemia: Systematic Review, Meta-Analysis and Re-Analysis with Novel Small RNA-Seq Tools

Kyriakidis

Tsezou

2022

Cancers

View full text Add to dashboard Cite

MicroRNAs (miRNAs) have been implicated in childhood acute lymphoblastic leukemia (ALL) pathogenesis. We performed a systematic review and meta-analysis of miRNA single-nucleotide polymorphisms (SNPs) in childhood ALL compared with healthy children, which revealed (i) that the CC genotype of rs4938723 in pri-miR-34b/c and the TT genotype of rs543412 in miR-100 confer protection against ALL occurrence in children; (ii) no significant association between rs2910164 genotypes in miR-146a and childhood ALL; and (iii) SNPs in DROSHA, miR-449b, miR-938, miR-3117 and miR-3689d-2 genes seem to be associated with susceptibility to B-ALL in childhood. A review of published literature on differential expression of miRNAs in children with ALL compared with controls revealed a significant upregulation of the miR-128 family, miR-130b, miR-155, miR-181 family, miR-210, miR-222, miR-363 and miR-708, along with significant downregulation of miR-143 and miR-148a, seem to have a definite role in childhood ALL development. MicroRNA signatures among childhood ALL subtypes, along with differential miRNA expression patterns between B-ALL and T-ALL cases, were scrutinized. With respect to T-ALL pediatric cases, we reanalyzed RNA-seq datasets with a robust and sensitive pipeline and confirmed the significant differential expression of hsa-miR-16-5p, hsa-miR-19b-3p, hsa-miR-92a-2-5p, hsa-miR-128-3p (ranked first), hsa-miR-130b-3p and -5p, hsa-miR-181a-5p, -2-3p and -3p, hsa-miR-181b-5p and -3p, hsa-miR-145-5p and hsa-miR-574-3p, as described in the literature, along with novel identified miRNAs.

show abstract

“…One group has attempted a novel therapeutic approach based on delivering selected factors in EVs with some promising results. This group engineered EVs to deliver anti-HIV Env antibodies with either an apoptosisinducing miRNA (miR-143) or the chemotherapy compound curcumin, which has been shown to have anti-HIV activity, as well as anti-inflammatory and anti-tumor effects (Liang et al, 2016;Mantzorou et al, 2018;Tan et al, 2019). This group found that they could indeed target Env-expressing cells with exosomes containing the anti-Env antibody and if the exosomes also contained curcumin, the Env-positive cells died (Zou et al, 2019).…”

Section: The Viral Modified Proteinaceous Cargo Of Evs Dictates Novelmentioning

confidence: 99%

Cloaked Viruses and Viral Factors in Cutting Edge Exosome-Based Therapies

Dogrammatzis

Waisner

Kalamvoki

2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Extracellular vesicles (EVs) constitute a heterogeneous group of vesicles released by all types of cells that play a major role in intercellular communication. The field of EVs started gaining attention since it was realized that these vesicles are not waste bags, but they carry specific cargo and they communicate specific messages to recipient cells. EVs can deliver different types of RNAs, proteins, and lipids from donor to recipient cells and they can influence recipient cell functions, despite their limited capacity for cargo. EVs have been compared to viruses because of their size, cell entry pathways, and biogenesis and to viral vectors because they can be loaded with desired cargo, modified, and re-targeted. These properties along with the fact that EVs are stable in body fluids, they can be produced and purified in large quantities, they can cross the blood-brain barrier, and autologous EVs do not appear to cause major adverse effects, have rendered them attractive for therapeutic use. Here, we discuss the potential for therapeutic use of EVs derived from virus infected cells or EVs carrying viral factors. We have focused on six major concepts: (i) the role of EVs in virus-based oncolytic therapy or virus-based gene delivery approaches; (ii) the potential use of EVs for developing viral vaccines or optimizing already existing vaccines; (iii) the role of EVs in delivering RNAs and proteins in the context of viral infections and modulating the microenvironment of infection; (iv) how to take advantage of viral features to design effective means of EV targeting, uptake, and cargo packaging; (v) the potential of EVs in antiviral drug delivery; and (vi) identification of novel antiviral targets based on EV biogenesis factors hijacked by viruses for assembly and egress. It has been less than a decade since more attention was given to EV research and some interesting concepts have already been developed. In the coming years, additional information on EV biogenesis, how they are hijacked and utilized by pathogens, and their impact on the microenvironment of infection is expected to indicate avenues to optimize existing therapeutic tools and develop novel approaches.

show abstract

miRNA143 Induces K562 Cell Apoptosis Through Downregulating BCR-ABL

Cited by 8 publications

References 28 publications

Delivery of therapeutic RNA by extracellular vesicles derived from Saccharomyces cerevisiae for Medicine Applications

Delivery of therapeutic RNA by extracellular vesicles derived from Saccharomyces cerevisiae for Medicine Applications

MicroRNAs and the Diagnosis of Childhood Acute Lymphoblastic Leukemia: Systematic Review, Meta-Analysis and Re-Analysis with Novel Small RNA-Seq Tools

Cloaked Viruses and Viral Factors in Cutting Edge Exosome-Based Therapies

Contact Info

Product

Resources

About